Dr.Reddy’s Laboratories (RDY) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Dr.Reddy’s Laboratories (NYSE:RDY) from an overweight rating to an equal weight rating in a research note released on Monday, BenzingaRatingsTable reports.
Several other research analysts have also recently issued reports on RDY. Zacks Investment Research cut shares of Dr.Reddy’s Laboratories from a buy rating to a hold rating in a report on Monday, April 8th. TheStreet raised shares of Dr.Reddy’s Laboratories from a c+ rating to a b rating in a report on Friday, February 1st. Finally, CL King raised shares of Dr.Reddy’s Laboratories from a neutral rating to a buy rating in a report on Monday, February 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $44.00.
NYSE RDY opened at $37.01 on Monday. The stock has a market cap of $6.54 billion, a P/E ratio of 22.57 and a beta of 0.13. Dr.Reddy’s Laboratories has a 52-week low of $28.13 and a 52-week high of $42.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.81 and a quick ratio of 1.26.
About Dr.Reddy’s Laboratories
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.